---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-024301"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:06:38.537355+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CorMedix reports Q4 2022 net loss $8.2M; FDA grants Type A meeting for DefenCath resubmission

## Summary
- Q4 2022 net loss $8.2M ($0.20/shr) vs $7.8M loss in Q4 2021; full-year net loss $29.7M ($0.74/shr).
- Cash and short-term investments $58.8M at Dec 31, 2022; $7.2M raised via ATM in Q1 2023.
- FDA granted Type A meeting in mid-April to discuss DefenCath NDA resubmission; CMO corrective actions completed.
- Agreement with Siegfried AG (Hameln, Germany) as backup CMO for DefenCath manufacturing.
- Promoted Erin Mistry to EVP/Chief Commercial Officer and Dr. Tushar Mukherjee to SVP/Head of Technical Operations.

## SEC filing metadata
- accession: 0001213900-23-024301
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/0001213900-23-024301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/ea176049-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-024301
- JSON: https://secwatch.observer/filing/0001213900-23-024301.json
- Plain text: https://secwatch.observer/filing/0001213900-23-024301.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt, EPS $0.20 per share.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Net income: net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt
  - EPS: $0.20 per share
  - Result: reported results
  source text: CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390023024301/0001213900-23-024301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.